Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin
Background: Doxorubicin, an anthracycline chemotherapeutic agent, is widely used in the treatment of many cancers. However, doxorubicin posts a great risk of adverse cardiovascular events, which are thought to be caused by oxidative stress. We recently reported that the ubiquitin E3 ligase TRIM21 in...
Main Authors: | Kai Hou, Jianliang Shen, Junrong Yan, Chuannan Zhai, Jingxia Zhang, Ji-An Pan, Ye Zhang, Yaping Jiang, Yongbo Wang, Richard Z. Lin, Hongliang Cong, Shenglan Gao, Wei-Xing Zong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | EBioMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396421002498 |
Similar Items
-
Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments
by: Guoxia Zhang, et al.
Published: (2022-06-01) -
Inhibition of METTL3 ameliorates doxorubicin-induced cardiotoxicity through suppression of TFRC-mediated ferroptosis
by: Lin Wu, et al.
Published: (2024-06-01) -
TRIM21‐Promoted FSP1 Plasma Membrane Translocation Confers Ferroptosis Resistance in Human Cancers
by: Jun Gong, et al.
Published: (2023-10-01) -
Taxifolin protects against doxorubicin-induced cardiotoxicity and ferroptosis by adjusting microRNA-200a-mediated Nrf2 signaling pathway
by: Zhihui Lin, et al.
Published: (2023-11-01) -
Lipidomics application to explain acute cardiotoxicity induced by doxorubicin
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01)